Skip to content
To the full analysis

City Therapeutics Stock: Growth

CTY
$18.35Closing price of 19 Nov 2026MEQIRI Score 58 out of 100

City Therapeutics reported $8.16B in revenue for fiscal 2019, down 4% on the prior year, down 1.6% a year on average over up to five years. That makes four years of decline in a row.

Daily figure as of 20 Nov 2026

Revenue (Annual rate)
−1.5%
per year from 2005 to 2019
Earnings (Annual rate)
4.6%
per year from 2005 to 2019
Free cash flow (Annual rate)
0.3%
per year from 2005 to 2019

Growth per Year by Period

What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.

since 2014since 2009since 2005
Revenue−1.6%−1.7%−1.5%
Revenue per shareno datano datano data
Earnings13.5%4.3%4.6%
Earnings per shareno datano datano data
Free cash flow6.8%1.0%0.3%
Free cash flow per shareno datano datano data

Growth Over Time

Revenue is 12% below its high of $9.27B in 2010. City Therapeutics has made a profit in every fiscal year since 2005. In the quarter to 30 Jun 2020 revenue fell 74.5% on the prior year quarter, after an average of minus 4.7% in the four quarters before.

Fiscal Years at a Glance

How Revenue and Earnings Grow

  • Revenue
  • Earnings
  • Free cash flow
Figures as a table
YearRevenueEarningsFree cash flow
2005$10.05B$977M$2.18B
2006$9.87B$1.2B$1.95B
2007$9.88B$1.49B$2.22B
2008$10.39B$1.44B$2.08B
2009$9.73B$1.2B$2.06B
2010$9.27B$1.08B$2B
2011$6.64B$543M$1.17B
2012$8.85B$849M$1.51B
2013$8.75B$964M$1.45B
2014$8.84B$970M$1.64B
2015$8.96B$1.07B$1.34B
2016$8.91B$1.09B$1.39B
2017$8.55B$1.66B$1.11B
2018$8.49B$1.67B$2.75B
2019$8.16B$1.83B$2.28B

Revenue by Segment

How City Therapeutics Inc. makes its money and how that has shifted. Names are as the company reports them.

  • Legacy Services$3.5B39%
  • Strategic Services$3.3B37%
  • Affiliates and Other Services$2.1B24%

The company split earlier years differently. A history would not be comparable, so only 2012 is shown.

Figures as a table
2012Share 2012
Legacy Services$3.47B39.2%
Strategic Services$3.27B36.9%
Affiliates and Other Services$2.11B23.9%
Total revenue$8.85B100%

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2019. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.